Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome

Journal of Experimental Medicine

Volumn 210, Issue 11, 2013, Pages 2273-2288

  Fabbri, Giulia ^a   Khiabanian, Hossein ^b   Holmes, Antony B ^a   Wang, Jiguang ^b   Messina, Monica ^a,c   Mullighan, Charles G ^d   Pasqualucci, Laura ^a   Rabadan, Raul ^b   Dalla Favera, Riccardo ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; NOTCH1 RECEPTOR;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME LOSS; CHRONIC LYMPHATIC LEUKEMIA; CLONAL EVOLUTION; COPY NUMBER VARIATION; EXOME; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; RICHTER SYNDROME; TUMOR SUPPRESSOR GENE;

APOPTOSIS REGULATORY PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; OPEN READING FRAMES; POINT MUTATION; RNA-BINDING PROTEINS; SYNDROME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886851785     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20131448     Document Type: Article

References (76)

1. Annunziata, C.M., R.E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, et al. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 12:115-130. http://dx.doi.org/10.1016/j.ccr.2007.07.004
2. Aparicio, S., and C. Caldas. 2013. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368:842-851. http://dx.doi.org/10.1056/NEJMra1204892
3. Baumann, P., and T.R. Cech. 2001. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science. 292:1171-1175. http://dx.doi.org/10.1126/science.1060036
4. Berger, M.F., E. Hodis, T.P. Heffernan, Y.L. Deribe, M.S. Lawrence, A. Protopopov, E. Ivanova, I.R. Watson, E. Nickerson, P. Ghosh, et al. 2012. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 485:502-506.
5. Bergsagel, P.L., and W.M. Kuehl. 2013. Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity. Leukemia. (Epub ahead of print).
6. Berlin, I., H. Schwartz, and P.D. Nash. 2010. Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8·STAM complex. J. Biol. Chem. 285:34909-34921. http://dx.doi.org/10.1074/jbc. M109.016287
7. Beroukhim, R., G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh, D. Linhart, I. Vivanco, J.C. Lee, J.H. Huang, S. Alexander, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA. 104:20007-20012. http://dx.doi.org/10.1073/pnas.0710052104
8. Bories, J.C., D.M. Willerford, D. Grévin, L. Davidson, A. Camus, P. Martin, D. Stéhelin, and F.W. Alt. 1995. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature. 377:635-638. http://dx.doi.org/10.1038/377635a0
9. Carlotti, E., D. Wrench, J. Matthews, S. Iqbal, A. Davies, A. Norton, J. Hart, R. Lai, S. Montoto, J.G. Gribben, et al. 2009. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 113:3553-3557. http://dx.doi.org/10.1182/blood-2008-08-174839
10. Challa-Malladi, M., Y.K. Lieu, O. Califano, A.B. Holmes, G. Bhagat, V.V. Murty, D. Dominguez-Sola, L. Pasqualucci, and R. Dalla-Favera. 2011. Combined genetic inactivation of ?2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 20:728-740. http://dx.doi.org/10.1016/j.ccr.2011.11.006
11. Coiffier, B., E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-242. http://dx.doi.org/10.1056/NEJMoa011795
12. Davies, A.J., A. Rosenwald, G. Wright, A. Lee, K.W. Last, D.D. Weisenburger, W.C. Chan, J. Delabie, R.M. Braziel, E. Campo, et al. 2007. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br. J. Haematol. 136:286-293. http://dx.doi.org/10.1111/j.1365-2141.2006.06439.x
13. Domen, J., N.M. van der Lugt, D. Acton, P.W. Laird, K. Linders, and A. Berns. 1993. Pim-1 levels determine the size of early B lymphoid compartments in bone marrow. J. Exp. Med. 178:1665-1673. http://dx.doi.org/10.1084/jem.178.5.1665
14. Edelmann, J., K. Holzmann, F. Miller, D. Winkler, A. Bühler, T. Zenz, L. Bullinger, M.W. Kühn, A. Gerhardinger, J. Bloehdorn, et al. 2012. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 120:4783-4794. http://dx.doi.org/10.1182/blood-2012-04-423517
15. Fabbri, G., S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian, J. Ma, A. Grunn, M. Fangazio, D. Capello, S. Monti, et al. 2011. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208:1389-1401. http://dx.doi.org/10.1084/jem.20110921
16. Fine, B., C. Hodakoski, S. Koujak, T. Su, L.H. Saal, M. Maurer, B. Hopkins, M. Keniry, M.L. Sulis, S. Mense, et al. 2009. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science. 325:1261-1265. http://dx.doi.org/10.1126/science.1173569
17. Golas, M.M., B. Sander, C.L. Will, R. Lührmann, and H. Stark. 2003. Molecular architecture of the multiprotein splicing factor SF3b. Science. 300:980-984. http://dx.doi.org/10.1126/science.1084155
18. Grasso, C.S., Y.M. Wu, D.R. Robinson, X. Cao, S.M. Dhanasekaran, A.P. Khan, M.J. Quist, X. Jing, R.J. Lonigro, J.C. Brenner, et al. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239-243. http://dx.doi.org/10.1038/nature11125
19. Hallek, M., B.D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Döhner, P. Hillmen, M.J. Keating, E. Montserrat, K.R. Rai, and T.J. Kipps; International Workshop on Chronic Lymphocytic Leukemia. 2008.Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 111:5446-5456. http://dx.doi.org/10.1182/blood-2007-06-093906
20. Hannon, G.J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 371:257-261. http://dx.doi.org/10.1038/371257a0
21. Hans, C.P., D.D. Weisenburger, T.C. Greiner, R.D. Gascoyne, J. Delabie, G. Ott, H.K. Müller-Hermelink, E. Campo, R.M. Braziel, E.S. Jaffe, et al. 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275-282. http://dx.doi.org/10.1182/blood-2003-05-1545
22. He, L., J.M. Thomson, M.T. Hemann, E. Hernando-Monge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S.W. Lowe, G.J. Hannon, and S.M. Hammond. 2005. A microRNA polycistron as a potential human oncogene. Nature. 435:828-833. http://dx.doi.org/10.1038/nature03552
23. Huang, W., B.T. Sherman, and R.A. Lempicki. 2009a. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1-13. http://dx.doi.org/10.1093/nar/gkn923
24. Huang, W., B.T. Sherman, and R.A. Lempicki. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57. http://dx.doi.org/10.1038/nprot.2008.211
25. Huang, F.W., E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, and L.A. Garraway. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science. 339:957-959. http://dx.doi.org/10.1126/science.1229259
26. Keats, J.J., R. Fonseca, M. Chesi, R. Schop, A. Baker, W.J. Chng, S. Van Wier, R. Tiedemann, C.X. Shi, M. Sebag, et al. 2007. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 12:131-144. http://dx.doi.org/10.1016/j.ccr.2007.07.003
27. Kikushige, Y., F. Ishikawa, T. Miyamoto, T. Shima, S. Urata, G. Yoshimoto, Y. Mori, T. Iino, T. Yamauchi, T. Eto, et al. 2011. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 20:246-259. http://dx.doi.org/10.1016/j.ccr.2011.06.029
28. Kulis, M., S. Heath, M. Bibikova, A.C. Queirós, A. Navarro, G. Clot, A. Martínez-Trillos, G. Castellano, I. Brun-Heath, M. Pinyol, et al. 2012. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44:1236-1242. http://dx.doi.org/10.1038/ng.2443
29. Küppers, R., and R. Dalla-Favera. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 20:5580-5594. http://dx.doi.org/10.1038/sj.onc.1204640
30. Kuroda, K., H. Han, S. Tani, K. Tanigaki, T. Tun, T. Furukawa, Y. Taniguchi, H. Kurooka, Y. Hamada, S. Toyokuni, and T. Honjo. 2003. Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity. 18:301-312. http://dx.doi.org/10.1016/S1074-7613(03)00029-3
31. Landau, D.A., S.L. Carter, P. Stojanov, A. McKenna, K. Stevenson, M.S. Lawrence, C. Sougnez, C. Stewart, A. Sivachenko, L. Wang, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 152:714-726. http://dx.doi.org/10.1016/j.cell.2013.01.019
32. Li, H., and R. Durbin. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 26:589-595. http://dx.doi.org/10.1093/bioinformatics/btp698
33. Lohr, J.G., P. Stojanov, M.S. Lawrence, D. Auclair, B. Chapuy, C. Sougnez, P. Cruz-Gordillo, B. Knoechel, Y.W. Asmann, S.L. Slager, et al. 2012. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA. 109:3879-3884. http://dx.doi.org/10.1073/pnas.1121343109
34. Lui, T.T., C. Lacroix, S.M. Ahmed, S.J. Goldenberg, C.A. Leach, A.M. Daulat, and S. Angers. 2011. The ubiquitin-specific protease USP34 regulates axin stability and Wnt/?-catenin signaling. Mol. Cell. Biol. 31:2053-2065. http://dx.doi.org/10.1128/MCB.01094-10
35. Monti, S., B. Chapuy, K. Takeyama, S.J. Rodig, Y. Hao, K.T. Yeda, H. Inguilizian, C. Mermel, T. Currie, A. Dogan, et al. 2012. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 22:359-372. http://dx.doi.org/10.1016/j.ccr.2012.07.014
36. Mootha, V.K., C.M. Lindgren, K.F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34:267-273. http://dx.doi.org/10.1038/ng1180
37. Morin, R.D., M. Mendez-Lago, A.J. Mungall, R. Goya, K.L. Mungall, R.D. Corbett, N.A. Johnson, T.M. Severson, R. Chiu, M. Field, et al. 2011. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 476:298-303. http://dx.doi.org/10.1038/nature10351
38. Ouillette, P., S. Fossum, B. Parkin, L. Ding, P. Bockenstedt, A. Al-Zoubi, K. Shedden, and S.N. Malek. 2010. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin. Cancer Res. 16:835-847. http://dx.doi.org/10.1158/1078-0432.CCR-09-2534
39. Ouillette, P., K. Saiya-Cork, E. Seymour, C. Li, K. Shedden, and S.N. Malek. 2013. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin. Cancer Res. 19:2893-2904. http://dx.doi.org/10.1158/1078-0432.CCR-13-0138
40. Palomero, T., W.K. Lim, D.T. Odom, M.L. Sulis, P.J. Real, A. Margolin, K.C. Barnes, J. O'Neil, D. Neuberg, A.P. Weng, et al. 2006. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA. 103:18261-18266. http://dx.doi.org/10.1073/pnas.0606108103
41. Pasqualucci, L., V. Trifonov, G. Fabbri, J. Ma, D. Rossi, A. Chiarenza, V.A. Wells, A. Grunn, M. Messina, O. Elliot, et al. 2011. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43:830-837. http://dx.doi.org/10.1038/ng.892
42. Puente, X.S., M. Pinyol, V. Quesada, L. Conde, G.R. Ordóñez, N. Villamor, G. Escaramis, P. Jares, S. Beà, M. González-Díaz, et al. 2011. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 475:101-105. http://dx.doi.org/10.1038/nature10113
43. Quesada, V., L. Conde, N. Villamor, G.R. Ordóñez, P. Jares, L. Bassaganyas, A.J. Ramsay, S. Beà, M. Pinyol, A. Martínez-Trillos, et al. 2012. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44:47-52. http://dx.doi.org/10.1038/ng.1032
44. Ramsay, A.J., V. Quesada, M. Foronda, L. Conde, A. Martínez-Trillos, N. Villamor, D. Rodríguez, A. Kwarciak, C. Garabaya, M. Gallardo, et al. 2013. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 45:526-530. http://dx.doi.org/10.1038/ng.2584
45. Rausch, T., D.T. Jones, M. Zapatka, A.M. Stütz, T. Zichner, J. Weischenfeldt, N. Jäger, M. Remke, D. Shih, P.A. Northcott, et al. 2012. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 148:59-71. http://dx.doi.org/10.1016/j.cell.2011.12.013
46. Rawlings, D.J., M.A. Schwartz, S.W. Jackson, and A. Meyer-Bahlburg. 2012. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12:282-294. http://dx.doi.org/10.1038/nri3190
47. Rossi, D., and G. Gaidano. 2009. Richter syndrome: molecular insights and clinical perspectives. Hematol. Oncol. 27:1-10. http://dx.doi.org/10.1002/hon.880
48. Rossi, D., M. Cerri, D. Capello, C. Deambrogi, F.M. Rossi, A. Zucchetto, L. De Paoli, S. Cresta, S. Rasi, V. Spina, et al. 2008. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br. J. Haematol. 142:202-215. http://dx.doi.org/10.1111/j.1365-2141.2008.07166.x
49. Rossi, D., A. Bruscaggin, V. Spina, S. Rasi, H. Khiabanian, M. Messina, M. Fangazio, T. Vaisitti, S. Monti, S. Chiaretti, et al. 2011a. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 118:6904-6908. http://dx.doi.org/10.1182/blood-2011-08-373159
50. Rossi, D., V. Spina, C. Deambrogi, S. Rasi, L. Laurenti, K. Stamatopoulos, L. Arcaini, M. Lucioni, G.B. Rocque, Z.Y. Xu-Monette, et al. 2011b. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 117:3391-3401. http://dx.doi.org/10.1182/blood-2010-09-302174
51. Rossi, D., M. Fangazio, S. Rasi, T. Vaisitti, S. Monti, S. Cresta, S. Chiaretti, I. Del Giudice, G. Fabbri, A. Bruscaggin, et al. 2012a. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wildtype chronic lymphocytic leukemia. Blood. 119:2854-2862. http://dx.doi.org/10.1182/blood-2011-12-395673
52. Rossi, D., V. Spina, F. Forconi, D. Capello, M. Fangazio, S. Rasi, M. Martini, V. Gattei, A. Ramponi, L.M. Larocca, et al. 2012b. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. Int. J. Cancer. 130:3006-3010. http://dx.doi.org/10.1002/ijc.26322
53. Rossi, D., V. Trifonov, M. Fangazio, A. Bruscaggin, S. Rasi, V. Spina, S. Monti, T. Vaisitti, F. Arruga, R. Famà, et al. 2012c. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J. Exp. Med. 209:1537-1551. http://dx.doi.org/10.1084/jem.20120904
54. Saito, T., S. Chiba, M. Ichikawa, A. Kunisato, T. Asai, K. Shimizu, T. Yamaguchi, G. Yamamoto, S. Seo, K. Kumano, et al. 2003. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity. 18:675-685. http://dx.doi.org/10.1016/S1074-7613(03)00111-0
55. Samon, J.B., M. Castillo-Martin, M. Hadler, A. Ambesi-Impiobato, E. Paietta, J. Racevskis, P.H. Wiernik, J.M. Rowe, J. Jakubczak, S. Randolph, et al. 2012. Preclinical analysis of the ?-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol. Cancer Ther. 11:1565-1575. http://dx.doi.org/10.1158/1535-7163.MCT-11-0938
56. Schuh, A., J. Becq, S. Humphray, A. Alexa, A. Burns, R. Clifford, S.M. Feller, R. Grocock, S. Henderson, I. Khrebtukova, et al. 2012. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 120:4191-4196. http://dx.doi.org/10.1182/blood-2012-05-433540
57. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704-707. http://dx.doi.org/10.1038/366704a0
58. Sherr, C.J. 2004. Principles of tumor suppression. Cell. 116:235-246. http://dx.doi.org/10.1016/S0092-8674(03)01075-4
59. Stankovic, T., P. Weber, G. Stewart, T. Bedenham, J. Murray, P.J. Byrd, P.A. Moss, and A.M. Taylor. 1999. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 353:26-29. http://dx.doi.org/10.1016/S0140-6736(98)10117-4
60. Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102:15545-15550. http://dx.doi.org/10.1073/pnas.0506580102
61. Sun, X., H.F. Frierson, C. Chen, C. Li, Q. Ran, K.B. Otto, B.L. Cantarel, R.L. Vessella, A.C. Gao, J. Petros, et al. 2005. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat. Genet. 37:407-412. http://dx.doi.org/10.1038/ng1528
62. Swerdlow, S.H. 2008. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. International Agency for research on Cancer (IARC), Lyon Tiacci, E., V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, M.P. Martelli, A. Pucciarini, B. Bigerna, R. Pacini, V.A. Wells, et al. 2011. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364:2305-2315. http://dx.doi.org/10.1056/NEJMoa1014209
63. Tsimberidou, A.M., S. O'Brien, I. Khouri, F.J. Giles, H.M. Kantarjian, R. Champlin, S. Wen, K.A. Do, S.C. Smith, S. Lerner, et al. 2006. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J. Clin. Oncol. 24:2343-2351. http://dx.doi.org/10.1200/JCO.2005.05.0187
64. Tsimberidou, A.M., W.G. Wierda, W. Plunkett, R. Kurzrock, S. O'Brien, S. Wen, A. Ferrajoli, F. Ravandi-Kashani, G. Garcia-Manero, Z. Estrov, et al. 2008. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 26:196-203. http://dx.doi.org/10.1200/JCO.2007.11.8513
65. Vaux, D.L., S. Cory, and J.M. Adams. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:440-442. http://dx.doi.org/10.1038/335440a0
66. Walter, M.J., D. Shen, L. Ding, J. Shao, D.C. Koboldt, K. Chen, D.E. Larson, M.D. McLellan, D. Dooling, R. Abbott, et al. 2012. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366:1090-1098. http://dx.doi.org/10.1056/NEJMoa1106968
67. Wang, H., and H.C. Morse III. 2009. IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol. Res. 43:109-117. http://dx.doi.org/10.1007/s12026-008-8055-8
68. Wang, L., M.S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. Werner, A. Sivachenko, D.S. DeLuca, L. Zhang, et al. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365:2497-2506. http://dx.doi.org/10.1056/NEJMoa1109016
69. Weng, A.P., A.A. Ferrando, W. Lee, J.P. Morris IV, L.B. Silverman, C. Sanchez-Irizarry, S.C. Blacklow, A.T. Look, and J.C. Aster. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 306:269-271. http://dx.doi.org/10.1126/science.1102160
70. Wu, J.N., and C.W. Roberts. 2013. ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor? Cancer discovery. 3:35-43.
71. Wu, Y., C. Cain-Hom, L. Choy, T.J. Hagenbeek, G.P. de Leon, Y. Chen, D. Finkle, R. Venook, X. Wu, J. Ridgway, et al. 2010. Therapeutic antibody targeting of individual Notch receptors. Nature. 464:1052-1057. http://dx.doi.org/10.1038/nature08878
72. Xiao, C., L. Srinivasan, D.P. Calado, H.C. Patterson, B. Zhang, J. Wang, J.M. Henderson, J.L. Kutok, and K. Rajewsky. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9:405-414. http://dx.doi.org/10.1038/ni1575
73. Yano, T., E.S. Jaffe, D.L. Longo, and M. Raffeld. 1992. MYC rearrangements in histologically progressed follicular lymphomas. Blood. 80:758-767.
74. Zenz, T., B. Eichhorst, R. Busch, T. Denzel, S. Häbe, D. Winkler, A. Bühler, J. Edelmann, M. Bergmann, G. Hopfinger, et al. 2010. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28:4473-4479. http://dx.doi.org/10.1200/JCO.2009.27.8762
75. Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725-734. http://dx.doi.org/10.1016/S0092-8674(00)81401-4
76. Zhang, J., V. Grubor, C.L. Love, A. Banerjee, K.L. Richards, P.A. Mieczkowski, C. Dunphy, W. Choi, W.Y. Au, G. Srivastava, et al. 2013. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America.